Table 1.
Demographic and baseline characteristics (all treatment groups combined)
| Characteristic | LEI > 0 (N = 403) |
LDI-B > 0 (N = 155) |
Integrated analysis set (N = 679) |
|---|---|---|---|
| Age, mean years (SD)a | 51.2 (11.8) | 47.8 (12.1) | 51.0 (11.9) |
| Gender, n (%) | |||
| Male | 166 (41.2) | 70 (45.2) | 310 (45.7) |
| Race, n (%)a | |||
| White | 379 (94.0) | 142 (91.6) | 629 (92.8) |
| Black or African American | 1 (0.2) | 0 (0.0) | 3 (0.4) |
| Asian | 16 (4.0) | 12 (7.7) | 33 (4.9) |
| Other/multiple | 7 (1.7) | 1 (0.6) | 13 (1.9) |
| BMI, kg/m2, mean (SD)a | 31.2 (7.8) | 29.9 (7.3) | 30.2 (7.3) |
| cDMARD experience, n (%) | 231 (57.3) | 96 (61.9) | 385 (56.7) |
| MTX at baseline, n (%) | 192 (47.6) | 81 (52.3) | 318 (46.8) |
| Time since PsA onset, mean years (SD) | 11.0 (8.8) | 9.7 (8.0) | 11.0 (9.3) |
| Active PSO with BSA ≥ 3%, n (%)a | 241 (65.7) | 105 (74.5) | 402 (65.4) |
| Tender joint count (68 joints), mean (SD)a | 25.2 (15.5) | 22.2 (13.5) | 22.0 (14.9) |
| Swollen joint count (66 joints), mean (SD)a | 12.5 (9.1) | 15.2 (11.3) | 11.9 (9.1) |
| Current enthesitis, n (%)a | 403 (100.0) | 108 (69.7) | 403 (59.7) |
| Current dactylitis, n (%)a | 108 (26.8) | 155 (100.0) | 155 (22.9) |
| Leeds Enthesitis Index, mean (SD)a,b | 2.9 (1.6) | 3.1 (1.6) | 2.9 (1.6) |
| Leeds Dactylitis Index-Basic, mean (SD)a,c | 58.2 (72.0) | 56.4 (68.3) | 56.4 (68.3) |
Abbreviations: BSA body surface area, BMI body mass index, cDMARD conventional disease-modifying antirheumatic drugs, LDI-B Leeds Dactylitis Index-Basic, LEI Leeds Enthesitis Index, MTX methotrexate, N population size, n number in group, PsA psoriatic arthritis, PSO psoriasis, SD standard deviation
aThere are patients with missing baseline information in some groups; the denominator of a particular baseline measure is the number of patients with non-missing baseline measures
bSummarized by patients with baseline enthesitis, defined as LEI score > 0
cSummarized by patients with baseline dactylitis, defined as LDI-B score > 0